Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

Revenio Interim Report Q2/2024

By Inderes8/8/2024, 12:00 PM
Revenio Group

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Jouni Toijala
00:01 - 04:19

Good afternoon from Sunny Hills, Inc. Welcome to the Revenio Group earnings call. My name is Jouni Toijala. I'm the Group CEO, and with me here as well is our Group CFO, Robin Pulkkinen. Today, we are going to go through the highlights of Q2. So I'm going to go through those. Then Robin is going to cover the financials, the shareholder structure change, and the financial guidance. So, let's jump to Q2. It was a good second quarter for us. Exactly according to the plan. Net sales were €25.4 million. An increase of 14.2% from last year. Q2 and the currency-adjusted growth was 13.5%. We got a bit of a tailwind from the US dollar. Operating profit was €5.3 million or 20.6% of net sales, up 12.6%. We had a write-off regarding Rent-A-Car here. Robin will go through the adjusted numbers a bit more in detail. EBITDA was at a really good level. Up 25.6%, as well as in Q1. Net cash flow from operations in Q2 was extremely good. So, €6.5 million, and earnings per share were up to 0.155% for the entire first half. Net sales of €49.1 million represent an increase of 7.9%. On currency-adjusted terms, the increase was 6.1% EBIT, €10.4 million was slightly down from last year's €13.3 million, and net cash flow. Extremely good, from €0.1 million to €11.2 million. This of course reflected a slight increase in earnings per share. Looking back at the business highlights for the second quarter of 2024. The sales development in the second quarter was strong, with sales growth particularly strong in the US. In Europe, the Middle East, and African APAC, The sales growth was very strong. If we examine the segments a bit more carefully, Sales of fundus imaging devices were very strong. Additionally, tonometers were developing and selling strongly during the quarter. Further, the devices leading the sales were outstanding. So we sold 200, including the probes, which were particularly popular. Well, then there's the agent family, which also sold really well. And then, if you recall back to Q4 last year. We also updated the new software version for our Windows Parametric called Compass, so we saw nice growth percentages on the perimetry side as well. Then, we launched the new product called the iCare TONOVET Pro. So that was launched during Q2, and sales are picking up nicely on that one as well. I'll let Robin go through the financial part and also cover it in more detail. So over to you, Robin.

Unknown 1
04:19 - 04:20

Thank you, Jouni.

Robin Pulkkinen
04:21 - 11:55

Jouni covered the numbers earlier in the slides. Maybe I'll give some more color here. So, sales were up 14.2%. In the second quarter, looking at the gross margin, it was very much in line with the top line growth. So, both the top line and gross margin grew for the full first six months and the second quarter, aligning with each other. Also, the gross margin was at a similar level to last year. So there were actually very few surprises there on the margin side. We did have some write-offs, as Jouni mentioned. During the quarter, we wrote down all non-strategic capitalizations that we had in the balance sheet. Mostly related to vintage Vertica. And that was $730,000. So, looking at operating income. Operating profit, the adjusted numbers are a better line to look at if you want to understand the core business performance. Coincidentally, last year in the same quarter, we had $800,000 in one-time project costs that impacted the numbers back then. Both of these figures have been adjusted in the adjusted operating profit line. So $6 million for the second quarter and $5.540 million for Q2 of 2023, resulting in approximately 9% growth. And for the whole year, for the first six months. There's a small decline still in the adjusted EBITDA number. I'll go through the other numbers in more detail in the later slides. So basically a good quarter. Very much in line with what we and the market expected. So, as we said earlier, we are going into the year. Q1 and Q4 were challenging from a comparability point of view. And then, in Q2 and Q3, we noted the quarters wherein there was potential for better growth. Um, so basically, looking at the numbers, how they came in, it was very much according to our initial and internal thinking, also how we thought the year would be going. So, year to date, things are going as planned with FX-adjusted growth at 13.5%, as you already mentioned. It's also nice to see that the Q2 top line is coming back closer to the trend line. Q2 has often been below the trend line in earlier years as well. 2022 was an exceptional year where that was not the case. So, uh, exceptionally good year in 2022. Standing out here is also reflected in the graph. Um, so looking at the profitability, also with a bit of a longer tail, now going back from 5.1 million to 6 million in the second quarter. And basically, typically looking back at the earlier years, the second quarter has always been stronger than the first quarter for us. From a profit point of view. Last year was an exception in that regard. So you can see here also that last year, the Q2 was kind of soft from a performance point of view. This year, just as a reminder, the cost side for us, particularly personnel expenses, is expected to grow mainly due to very little bonus accruals included in the numbers for the 2023 performance. So hopefully this year we will deliver as we planned and have guided, so most likely those costs will go up. As mentioned earlier, we have budgeted between 1.5 to 2 million dollars for clinical trial costs this year, though it is still a bit open. How that's going to play out in the second half. There was very little in Q2, quite a bit in Q1. Towards the end of the year, we will likely incur some costs impacting our numbers due to clinical trials. Um, but those plans are still somewhat open, and we do not have full visibility yet into how that's going to play out in the coming months. Uh, cash flow. Excellent. Looking at last year, Q1 was positive at 300,000. Q2 was negative, actually. This year, we're above 11 million for the same two quarters. Um, there are basically a few reasons. Typically, in Q1, incentive payments for the entire company are distributed based on the previous year's performance. So that typically brings down the Q1 number. This year, there were significantly lower payments related to those. Um, also the working capital has been improved. In Q2, net income was higher than in the comparable period, playing into their advantage. Just a reminder, last year's Q2 cash flow was impacted by the Italian subsidiary's income tax payments. The tax system there is a bit different. We did make some payments related to the earlier years. These were not payments for 2023, but for 2022, which also affected the Q2 numbers last year. But overall, the results were very good, if not record-setting. The first half had excellent cash flow. The balance sheet continues to get stronger over the last quarters. We're approaching a 75% equity ratio with net gearing below zero. We paid out the dividend. Based on the AGM on April 4th, a dividend of $0.38 was paid out. The dividend payout ratio was slightly above 50%. This is one of the reasons why the equity ratio has continued to grow. Regarding shareholders, there hasn't been much change here. William Demant Invest A/S bought some more shares. Not a significant amount. However, foreign ownership has grown by 0.7 or 0.8% from the end of Q1. The first five companies or owners are in the same positions as in Q1, albeit in a slightly different order from 6 to 10. Ownership at these ranks is very similar, and only William Demant Invest A/S is a clear major shareholder. Then the ownership splits into much smaller pieces after that. Our guidance remains unchanged. Revenue growth, with exchange rate adjustments, and net sales are estimated to grow by 5 to 10% from the previous year, while profitability, excluding non-recurring items, is estimated to remain at a good level. Great.

Jouni Toijala
11:55 - 11:59

Thank you, Robin. I think it's time for the questions, please.

Operator
12:04 - 12:28

If you wish to ask a question, please press the pound key and the number five on your telephone keypad to enter the queue. If you wish to withdraw your question, please press the pound key and the number six on your telephone keypad. The next question comes from Nicole Kangas from SEB Funds. Please go ahead.

Nicole Kangas
12:29 - 13:03

This is Nicole from SEB Funds. Thank you for the presentation. I have a couple of questions. Starting with that, you mentioned in the report that you have seen increasing momentum in peer-driven clients. Even though they have not realized the larger orders yet. At what level is this segment now compared to, for example, two years back? And when do you expect those larger deliveries to be realized?

Jouni Toijala
13:04 - 14:05

Hi, Nick. So thanks for the question. If we first go one year back, it was in a total standstill, and then if you go two years back, they were quite active. What's the difference now compared to last year? It's a twofold. They are more active in putting the RFI and RFQ out. And then they have started to order smaller amounts. So, they are rolling out smaller amounts than they used to two years ago, but slightly higher than one year ago. And that's the current status. So activity is definitely not at the level that it used to be two years ago. But there is better activity than one year ago.

Nicole Kangas
14:07 - 14:14

So it's not only expected growth in Q2 then?

Jouni Toijala
14:15 - 14:30

Yes, that's right. If you were thinking that one. That's completely correct. We were able to grow the business strongly in the US, Europe, the Middle East, and the Africa APAC region.

Unknown 2
14:32 - 14:33

Yes, yes.

Nicole Kangas
14:34 - 14:51

Great, thanks. Then, if you look at the demand environment in Q3, as we have now entered Q3 and compare it to Q2, have there been any changes, or how do you view the environment for exits?

Jouni Toijala
14:52 - 15:22

We are executing according to the plan. Of course, it's only one month into Q3, but it's going according to the plan we set for the first, second, and third quarters. So, executing as we planned. So no hiccups so far for Q3 or anything else to add.

Robin Pulkkinen
15:23 - 15:41

Yes, variation is significant between single months. So it's difficult to say how the second half will go. But no, there's no reason to be alarmed from our end at least. So everything seems to be going pretty much as planned, like Jouni said.

Nicole Kangas
15:43 - 16:09

Okay, thanks. Then, a question regarding the composition of internal meters. So, well, you say that so far. No, there's no reason to be alarmed, but have you felt your sales or competitive position has been pressured by increased competition? And have you seen an increase in price competition on that front?

Jouni Toijala
16:10 - 17:45

I think it's good to structure this one, perhaps, in two ways. So, perhaps looking even from the product perspective. On the denominator side, we haven't seen any sign that competition is having an impact on the sales in Europe because the competition has been active on the autonomy side already for two years, so no impact in Q1 and no impact in Q2. If you look at the US, we consider the autonomic side. So we have now had the competition full on during Q2. As can be seen from the numbers. So, there was no impact to the Q2 numbers, although competition is pricing more aggressively than we are. But as I said, and as we can see from the numbers, there has been no impact in the US as well. Concerning the fundus imaging setup, it's exactly the same as in Q1. So, the fundus imaging devices and then also the parametric device called the compass. We have been able to grow the business quite nicely also during Q2. So no change on that front. And as can be seen from the gross margin. We haven't been getting the growth via lowering the prices, I think that's fair to say, Robin.

Nicole Kangas
17:49 - 18:21

Yeah, I understand. Then, one last question for me. You mentioned SCA costs. Indeed, there were significant costs in Q2. So, were there any related costs in Q2 and how much is left for it? And do you expect, for example, the operating cost level in Q3 to be higher than in Q2?

Robin Pulkkinen
18:23 - 19:04

There's just very little. I don't have the exact number. Around 100,000 is probably a pretty accurate estimate. But we're still working on the exact schedule with the clinical research companies, so. It's impossible to give an exact split yet. It also depends a lot on how we manage to enroll patients, which is almost impossible to forecast accurately. Sometimes it's easier. Sometimes it takes a longer time. But we will advise as we move forward during the year how those are playing out. But so far the schedule is not fixed yet. Exactly for the second half.

Unknown 3
19:04 - 19:05

All right. So.

Nicole Kangas
19:06 - 19:11

We are talking about an additional €1 million that is expected to be realized.

Robin Pulkkinen
19:12 - 19:26

Potentially, or it could be very close to year end, possibly January. It's hard to predict exactly how the schedule will pan out, but that's a good working number. We will correct it if anything changes.

Nicole Kangas
19:28 - 19:31

All right. That's all from me at this point. Thanks.

Operator
19:36 - 19:43

The next question comes from Jack Reynolds Clark of RBC Capital Markets. Please go ahead.

Unknown 4
19:47 - 20:16

I appreciate you guys taking my questions, thank you. Now, I have three questions, please. Starting with revenue growth. You mentioned strong performance across fundus imaging devices and tonometers. I was wondering if you could provide a rough quantification of the growth between these two segments and also discuss the contribution to growth from the iCare DRSplus and iCare TONOVET Pro in Europe. Thank you.

Jouni Toijala
20:17 - 22:32

Should I start Robin, and then you can continue? Regarding fundus imaging, the growth in fundus imaging was very strong. We adhere to internal guidelines, but the growth was substantial. Hopefully, that sheds some light on the situation. On the fundus imaging side, the growth was very strong. If we look at the products that were selling well: iCare DRSplus and iCare TONOVET Pro were performing well. In that context, we also evaluate the comparative fundus parameters against last year. We have experienced strong growth in the fundus parameters segment as well. Turning to the tonometers, the iCare IC200, including the probes, were the growth leaders in that category. Regarding the solutions package, I'm referring to the iCare DRSplus and the iCare TONOVET Pro in the context of retina care. We secured many new clients in Europe in these areas, but due to the foundational business in fundus imaging and perimeter products expanding significantly, the contribution from the iCare TONOVET Pro to growth, compared to that of tonometers and fundus imaging devices, was not as significant. However, it is still showing steady growth. And then, if we look at the home growth as before. So also moving forward. Growing. But the base business, the much larger base business, has been growing extremely well. So, it kind of undermines the smaller segments. But Robin, would you like to add anything?

Robin Pulkkinen
22:32 - 22:34

No, I think it was a good answer.

Unknown 4
22:37 - 23:01

Uh, great. Uh, then my second question is just on guidance for the full year. Does the strength you've had in Q2 imply that the upper end of the 5 to 10% revenue growth guidance range could be more achievable for the full year? Could you share some details about what good profitability looks like?

Robin Pulkkinen
23:02 - 23:31

That's similar to what Johnny was referring to regarding the top-line growth. Unfortunately, we haven't outlined our objectives. Basically, we've stated that it's good now, and indeed, it has been good for many years, so it spans a quite wide range. Unfortunately, I can't give an exact number. Um, what is the range? It's something we use internally only, which we haven't opened. Yes.

Unknown 4
23:33 - 23:55

Fair enough. I thought I would try anyway. Could you share the feedback that I believe you were due to receive just after the previous call? Um, and I expect marketing approval in H2 of 2025. Yeah.

Jouni Toijala
23:55 - 25:10

So, recapping our strategy related to retina screening in the USA. So it's twofold. The first part of it is that we want to guarantee with many AI players that our fundus imaging device works with all the dominant AI platforms. So that track has been ongoing for a long time and hopefully we are going to see some movement on that one during Q1 2025. But it's a slightly black box for us because we are not applying for FDA approval. So, it's not entirely certain, but we will transparently go through that again in our next earnings call. And then the second part of the strategy is to apply for FDA approval for Elam, Doctors Plus+ theron for retinal eye treatments. And we are going to submit that application by ourselves. And the schedule remains unchanged. So working towards the second half of 2025.

Unknown 4
25:12 - 25:14

Fantastic. Thanks for taking the questions.

Operator
25:21 - 25:26

The next question comes from Joanie Sandoval from Nordica. In today's webcast, we're pleased to report significant growth in the second quarter, particularly in our flagship products like the iCare IC200 tonometer and the iCare DRSplus.

Unknown 5
25:28 - 25:56

Yeah, thanks. Thanks for the presentation. Uh, maybe still, question on the margins and all that. Uh, this could be a tough one, but, uh, is this now, you are just shy of 23% on the EBITDA. EBIT margin was 11% on adjusted EBIT margin level. So, is this a good level, or should we expect the normal seasonal pickup in margins during H2?

Robin Pulkkinen
25:57 - 26:30

If you look at the objectives we set, then yes, they are at a good level. But basically, the business is very scalable. So assuming that, the second half has always been better than the first half, that would kind of lead you to assume that the probability would also be higher. Especially, Q4 is typically when we do about 30 to 40% of our EBITDA. I don't have the exact number, but that's a significant portion of the entire year's profits that we typically make in the last quarter.

Unknown 5
26:32 - 26:44

Yes, that's correct. You had mentioned turnover at launch during Q2. If we are excluding the Maya. iCare IC200 tonometer. How many new product launches should we expect during H2?

Jouni Toijala
26:45 - 27:03

That's an interesting question. Unfortunately, he asked a very good question, but I am not able to answer that one. So let's keep our eyes and ears open. And then let's do the counting when we go to watch the end of the first half. So sorry.

Unknown 6
27:03 - 27:05

I would be really happy.

Jouni Toijala
27:05 - 27:09

To answer, but unfortunately I can't. But let's keep our eyes and ears open for that.

Unknown 5
27:11 - 27:25

Okay. And then, maybe a second tough one, the 8 million contingent liability that you have in your books. And, uh, I know that you are aiming to give some info during Q3, but is there any news on this front?

Unknown 7
27:25 - 27:26

Yes, I.

Jouni Toijala
27:26 - 27:27

Think that we are.

Unknown 7
27:27 - 27:28

Uh.

Jouni Toijala
27:28 - 27:53

Coming back to the latest update related to October. So when we are coming with the Q3 earnings release. So, that's the backpack side of the comms. Okay.

Robin Pulkkinen
27:54 - 28:00

No, no, no, I think you said on the books contingent, but it's actually off the books. So, it's not on the balance sheet.

Unknown 2
28:00 - 28:01

Yeah, yeah, yeah.

Unknown 5
28:03 - 28:22

Okay. Uh, then maybe a question about the larger German deal that you announced in 2023. Can you provide any insight into these deliveries and possible splits? You know how those have been affecting Q2, and should we expect a continued positive impact from here in H2?

Jouni Toijala
28:22 - 29:11

We have been steadily delivering, so of course, one part of the growth of that deal has been visible in the first half. But, I mean, it’s only one part of the growth. So, we are hopeful that we will continue to have deliveries during the second half, and even into 2025. But that's the status currently. So, just to mention, it's only one part of the coming growth because there's growth from the US and growth from APAC. And that was a European deal. So, it's going according to the set plan. So no surprises on that one.

Unknown 5
29:13 - 29:21

Okay. Maybe one technical question for Robin. Uh, about the tax rate. What should we expect in 2024 and going forward?

Robin Pulkkinen
29:23 - 30:09

That's a good question. Basically, we're conducting IP rearrangements within the group between legal entities, which will enable us to utilize all the costs across the company, also in taxation, if it makes sense. So in my view, in the coming years, the group income tax rate should go slightly down. Maybe I don't have the exact number. It depends on the road map that we have. My estimate at this time would be a decrease of 0 to 2%, or 0 to 1.5%.

Unknown 5
30:11 - 30:21

Okay, okay. That's clear. Last one for me. Any news on the M&A front? So, how does your pipeline look? On that front.

Unknown 8
30:22 - 30:23

Uh.

Jouni Toijala
30:23 - 31:15

Actively still working on it. Um, there are still slight differences in the views. Uh, what comes to the valuation? So I think that there still is a bit of an issue. So if we compare ourselves to almost all the other players. So I think almost everybody is reporting declining sales and quite low profitability, or even breaking even or recording negative EBITDA, yet they still believe that the valuation should remain the same. So I think that has still been a bit of a challenge. But we are working with Robin and the team on that front as well. Anything to add, Robin?

Unknown 9
31:15 - 31:15

No.

Unknown 5
31:18 - 31:20

Okay. That's all for me.

Jouni Toijala
31:20 - 31:21

Thanks for your name. Thank you for considering me for this task.

Operator
31:25 - 31:32

The next question comes from Pierre Ross and Christine Sami from Carnegie Investment Bank. The webcast commenced with an introduction by CEO Jouni Toijala, who summarized Revenio's financial performance in the second quarter of 2024.

Unknown 10
31:37 - 32:22

Hi, Jouni, and hi, Robin. Thank you for the presentation. Uh, a couple of questions still left for me. First of all, I'm going back to last year and the trouble or the standstill experienced with these private equity-driven optician chains. I would like to understand this segment in the U.S. Does it consist of many privately equity-driven optician chains, or are there only a few, which is causing this trouble or caused the trouble for you with stalling sales?

Robin Pulkkinen
32:23 - 32:34

Um, maybe I'll take that one. So in the US, it's not one. It's definitely more than a few. I don't know, we have only four or five.

Unknown 1
32:34 - 32:35

Chains.

Robin Pulkkinen
32:35 - 32:36

Basically.

Unknown 10
32:39 - 33:06

All right. For four to five changes. All right. Yeah. Then, I had questions regarding the clinical trials pending for Q2, Q3, and Q4. I think you answered that already? Um, good. Thank you.

Jouni Toijala
33:06 - 33:07

Thank you, Pam.

Operator
33:12 - 33:18

The next question comes from Daniel Chepstow from Danske Bank. Good afternoon, everyone, and thank you for joining today's webcast on Revenio's financial results for the second quarter of 2024.

Unknown 2
33:21 - 33:48

Hi, it's Daniel from Danske Bank. Uh, I have just one question. From my side, thinking about the proportion of recurring revenues you have in your business, I mean the probes, software, and AI. So has the proportion increased compared to maybe a year or two ago, or have these devices still contributed across all tiers of these recurring revenues as well?

Robin Pulkkinen
33:48 - 34:36

Yes, the probes represent, of course, the massive majority of the recurring revenues that we currently have. It has been like going back years, to when we only had tonometers. When I started nine years ago, it constituted about 23 to 24% of the sales, and it continued to grow, taking up roughly 2% more each year. So, about 24 to 26% to 28% of the total. Until today, the probes have actually been growing very strongly for years. Also, after we stopped reporting, um, I can't give you the exact number of how much the total share of the recurring revenue is, but it continues to increase.

Unknown 2
34:40 - 34:43

Okay, well, that's actually quite helpful. Thanks. That's all from my side.

Operator
34:51 - 34:57

The next question comes from Nicole Kangas from SEB. Good morning, ladies and gentlemen. Welcome to today's webcast on Revenio's Q2 2024 financial performance.

Nicole Kangas
34:59 - 35:25

Hello, this is Nick again. I have one additional question related to when they received a write-down. I see you now. Write it down. Uh, with no release costs? Or does it affect the P&L side in any way?

Robin Pulkkinen
35:26 - 35:52

Some minor costs for maintaining the patents, for example, are incurred. We will probably continue with this approach. It's a valuable technology. When we hopefully find one, At some point, we will still find a new home for it. So it's not like we totally discarded it. We will keep the patents active and see if we can find alternatives for the business to move elsewhere.

Jouni Toijala
35:53 - 36:13

And we still have a couple of extremely good clinical studies ongoing which are expected to report very positive results. That's our view, although these are not generating too much cost. So we only need to provide the devices, and that's it. But it's not having any impact at all.

Nicole Kangas
36:16 - 36:18

Okay, do you understand? That's all from me.

Jouni Toijala
36:19 - 36:39

Thank you. Thank you. It seems that we are done for today. Thank you for your participation. Thank you for the great questions. Let's come back when we have Q3 wrapped up. So thank you, and have a good early autumn. Thank you. Thank you. Bye.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…